Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection

Soul Study Group

doi:10.1016/j.cgh.2019.01.044

Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection

Soul Study Group

Research output: Contribution to journal › Short survey › peer-review

8 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.¹ In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.^2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.⁴ Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.

Original language	English
Pages (from-to)	2811-2813.e1
Journal	Clinical Gastroenterology and Hepatology
Volume	17
Issue number	13
DOIs	https://doi.org/10.1016/j.cgh.2019.01.044
Publication status	Published - 2019 Dec

Bibliographical note

Funding Information:
Funding This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). This investigator-initiated trial was provided the study drug from Bristol-Myers Squibb. Bristol-Myers Squibb had no role in the study design, data collection, and analysis. The authors retain full responsibility.

Publisher Copyright:
© 2019 AGA Institute

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cgh.2019.01.044

Cite this

@article{6d9309f78155441a9027b880e7b7d13f,

title = "Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection",

abstract = "Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.",

author = "{Soul Study Group} and Lee, {Hye Won} and Park, {Jun Yong} and Kim, {Sang Gyune} and Tak, {Won Young} and Yim, {Hyung Joon} and Jang, {Byoung Kuk} and Kim, {Moon Young} and Kim, {Byung Ik} and Lee, {Jin Woo} and Yoon, {Ki Tae} and Cheong, {Jae Youn} and Kwon, {So Young} and Kim, {Tae Yeob} and Bae, {Si Hyun} and Seo, {Yeon Seok} and Kwon, {Jung Hyun} and Kim, {Dong Joon} and Kim, {Ja Kyung} and Jeong, {Soung Won} and Sungmin Myoung and Ahn, {Sang Hoon} and Han, {Kwang Hyub}",

note = "Funding Information: Funding This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). This investigator-initiated trial was provided the study drug from Bristol-Myers Squibb. Bristol-Myers Squibb had no role in the study design, data collection, and analysis. The authors retain full responsibility. Publisher Copyright: {\textcopyright} 2019 AGA Institute",

year = "2019",

month = dec,

doi = "10.1016/j.cgh.2019.01.044",

language = "English",

volume = "17",

pages = "2811--2813.e1",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "13",

}

TY - JOUR

T1 - Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection

AU - Soul Study Group

AU - Lee, Hye Won

AU - Park, Jun Yong

AU - Kim, Sang Gyune

AU - Tak, Won Young

AU - Yim, Hyung Joon

AU - Jang, Byoung Kuk

AU - Kim, Moon Young

AU - Kim, Byung Ik

AU - Lee, Jin Woo

AU - Yoon, Ki Tae

AU - Cheong, Jae Youn

AU - Kwon, So Young

AU - Kim, Tae Yeob

AU - Bae, Si Hyun

AU - Seo, Yeon Seok

AU - Kwon, Jung Hyun

AU - Kim, Dong Joon

AU - Kim, Ja Kyung

AU - Jeong, Soung Won

AU - Myoung, Sungmin

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

N1 - Funding Information: Funding This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). This investigator-initiated trial was provided the study drug from Bristol-Myers Squibb. Bristol-Myers Squibb had no role in the study design, data collection, and analysis. The authors retain full responsibility. Publisher Copyright: © 2019 AGA Institute

PY - 2019/12

Y1 - 2019/12

N2 - Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.

AB - Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease.1 In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression.2,3 After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression.4 Few “prospective” studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.

UR - http://www.scopus.com/inward/record.url?scp=85075205037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075205037&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2019.01.044

DO - 10.1016/j.cgh.2019.01.044

M3 - Short survey

C2 - 30731195

AN - SCOPUS:85075205037

SN - 1542-3565

VL - 17

SP - 2811-2813.e1

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 13

ER -

Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this